Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 3177-3184

  Kust, Davor ^a   Prpić, Marin ^a   Murgić, Jure ^a   Jazvić, Marijana ^a   Jakšić, Blanka ^a   Krilić, Draz ^a   Bolanća, Ante ^a   Kusić, Zvonko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Clinical markers; Hypothyroidism; Levothyroxine substitution therapy; Predictive factor; Renal cell carcinoma; Sunitinib

Indexed keywords

ANTITHYROID AGENT; CREATININE; LEVOTHYROXINE; LIOTHYRONINE; SUNITINIB; THIAMAZOLE; THYROTROPIN; THYROXINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CLEAR CELL METASTATIC RENAL CELL CARCINOMA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY FUNCTION; KIDNEY METASTASIS; LONG TERM SURVIVAL; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SURVIVAL RATE; THYROID FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLINICAL MARKERS; COHORT ANALYSIS; KIDNEY CARCINOMA; KIDNEY TUMOR; LEVOTHYROXINE SUBSTITUTION THERAPY; METASTASIS; PATHOLOGY; PREDICTIVE FACTOR; TREATMENT OUTCOME;

CLINICAL MARKERS; HYPOTHYROIDISM; LEVOTHYROXINE SUBSTITUTION THERAPY; PREDICTIVE FACTOR; RENAL CELL CARCINOMA; SUNITINIB;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PYRROLES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906337591     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. Accessed 20 October 2013.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115-124, 2007.
3. Bianchi L, Rossi L, Tomao F, Papa A, Zoratto F and Tomao S: Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer 20(5): R233-245, 2013.
4. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R and Bjarnason G: Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1(2 Suppl): S41-S54, 2007.
5. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, Thielen B and Herrmann E: Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29(6): 807-813, 2011.
6. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G and Zielinski CC: Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3): 534-544, 2011.
7. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M and Mazzanti R: The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol 30(5): 704-710, 2012.
8. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, Bladou F and Gravis G: Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol 23(3): 714-721, 2012.
9. Clemons J, Gao D, Naam M, Breaker K, Garfield D and Flaig TW: Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer 10(4): 225-231, 2012.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22): 3584-3590, 2009.
11. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R and Bukowski RM: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99(1): 81-83, 2007.
12. Laurberg P, Andersen S, Bulow PI and Carle A: Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment. Drugs Aging 22: 23-38, 2005.
13. Shinohara N, Takahashi M, Kamishima T, Ikushima K, Otsuka N, Ishizu A, Shimizu C, Kanayama H and Nonomura K: The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer 104(2): 241-247, 2011.
14. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P and Schöffski P: The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 99(3): 448-454, 2008.
15. Vetter ML, Kaul S and Iqbal N: Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. Endocr Pract 14: 618-624, 2008.
16. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P and Fugazzola L: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92(9): 3531-3534, 2007.
17. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V and Rodien P: Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 160(3): 331-336, 2009.
18. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS and Weismann NJ: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291(2): 228-238, 2004.
19. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas SL and Dayan C: Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 174(1): 32-39, 2014.
20. Vrdoljak E, Rini B, Schmidinger M, Omrcen T, Torday L, Szczylik C and Sella A: Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anticancer Drugs 24(5): 431-440, 2013.
21. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26(32): 5204-5212, 2008.
22. McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C and Hoogwerf BJ: Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid 21: 837-843, 2011.
23. Mani S, Todd MB, Katz K and Poo WJ: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154(1): 35-40, 1995.